Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.

Cancer research (2020-04-29)
Hengbo Zhou, Melanie A Blevins, Jessica Y Hsu, Deguang Kong, Matthew D Galbraith, Andrew Goodspeed, Rachel Culp-Hill, Michael U J Oliphant, Dominique Ramirez, Lingdi Zhang, Jennyvette Trinidad-Pineiro, Lesley Mathews Griner, Rebecca King, Elena Barnaeva, Xin Hu, Noel T Southall, Marc Ferrer, Daniel L Gustafson, Daniel P Regan, Angelo D'Alessandro, James C Costello, Samarjit Patnaik, Juan Marugan, Rui Zhao, Heide L Ford

Metastasis is the major cause of mortality for patients with cancer, and dysregulation of developmental signaling pathways can significantly contribute to the metastatic process. The Sine oculis homeobox homolog 1 (SIX1)/eyes absent (EYA) transcriptional complex plays a critical role in the development of multiple organs and is typically downregulated after development is complete. In breast cancer, aberrant expression of SIX1 has been demonstrated to stimulate metastasis through activation of TGFβ signaling and subsequent induction of epithelial-mesenchymal transition (EMT). In addition, SIX1 can induce metastasis via non-cell autonomous means, including activation of GLI-signaling in neighboring tumor cells and activation of VEGFC-induced lymphangiogenesis. Thus, targeting SIX1 would be expected to inhibit metastasis while conferring limited side effects. However, transcription factors are notoriously difficult to target, and thus novel approaches to inhibit their action must be taken. Here we identified a novel small molecule compound, NCGC00378430 (abbreviated as 8430), that reduces the SIX1/EYA2 interaction. 8430 partially reversed transcriptional and metabolic profiles mediated by SIX1 overexpression and reversed SIX1-induced TGFβ signaling and EMT. 8430 was well tolerated when delivered to mice and significantly suppressed breast cancer-associated metastasis in vivo without significantly altering primary tumor growth. Thus, we have demonstrated for the first time that pharmacologic inhibition of the SIX1/EYA2 complex and associated phenotypes is sufficient to suppress breast cancer metastasis. SIGNIFICANCE: These findings identify and characterize a novel inhibitor of the SIX1/EYA2 complex that reverses EMT phenotypes suppressing breast cancer metastasis.

Número do produto
Descrição do produto

1-Methyl-2-pyrrolidinone, anhydrous, 99.5%
Duolink® In Situ Red Starter Kit Mouse/Rabbit
Poly(ethylene glycol), average Mn 400
Kolliphor® HS 15
Fluoroshield with DAPI, histology mounting medium
Anti-EYA2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Monoclonal Anti-EYA2 antibody produced in mouse, clone 2F8, purified immunoglobulin, buffered aqueous solution

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.